County-level access to opioid use disorder medications in medicare Part D (2010-2015).
Buprenorphine
/ administration & dosage
Health Services Accessibility
/ statistics & numerical data
Humans
Logistic Models
Medicare Part D
/ statistics & numerical data
Naltrexone
/ administration & dosage
Opiate Substitution Treatment
/ methods
Opioid-Related Disorders
/ drug therapy
Practice Patterns, Physicians'
/ statistics & numerical data
Residence Characteristics
Socioeconomic Factors
United States
access
buprenorphine
medicare
naltrexone
opioid use disorder
Journal
Health services research
ISSN: 1475-6773
Titre abrégé: Health Serv Res
Pays: United States
ID NLM: 0053006
Informations de publication
Date de publication:
04 2019
04 2019
Historique:
pubmed:
22
1
2019
medline:
30
1
2020
entrez:
22
1
2019
Statut:
ppublish
Résumé
To identify geographic disparities in access to opioid use disorder (OUD) treatment medications and county demographic and economic characteristics associated with access to buprenorphine and oral naltrexone prescribers in Medicare Part D. We utilized data from the Medicare Part D Prescription Drug Event Standard Analytic File (2010-2015). We used logistic regression to examine county-level access to OUD medication prescribers. There was a 5.6 percentage point increase in counties with access to an OUD prescriber over the study period. However, in 2015, 60 percent of US counties lacked access to a Medicare Part D buprenorphine prescriber and over 75 percent lacked access to an oral naltrexone prescriber. Increased access to OUD prescribers was largely concentrated in urban counties. Results of logistic regression indicate regional differences and potential racial disparities in access to OUD prescribers. To improve access to buprenorphine and naltrexone treatment for Medicare Part D enrollees, CMS may consider implementing educational and training initiatives focused on OUD treatment, offering training to obtain a buprenorphine waiver at no cost to providers, and sending targeted information to providers in low OUD treatment capacity areas.
Identifiants
pubmed: 30665272
doi: 10.1111/1475-6773.13113
pmc: PMC6407357
doi:
Substances chimiques
Buprenorphine
40D3SCR4GZ
Naltrexone
5S6W795CQM
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
390-398Subventions
Organisme : University of Georgia
Pays : International
Organisme : Indiana University
Pays : International
Informations de copyright
© Health Research and Educational Trust.
Références
Ann Fam Med. 2015 Jan-Feb;13(1):23-6
pubmed: 25583888
Am J Addict. 2004;13 Suppl 1:S42-66
pubmed: 15204675
Pain Pract. 2014 Mar;14(3):E106-15
pubmed: 24289539
J Subst Abuse Treat. 2015 Jan;48(1):104-11
pubmed: 25218919
Milbank Q. 2015 Sep;93(3):561-83
pubmed: 26350930
JAMA Psychiatry. 2016 Sep 1;73(9):990-2
pubmed: 27438334
Am J Public Health. 2015 Aug;105(8):e55-63
pubmed: 26066931
Subst Abuse Treat Prev Policy. 2013 Sep 23;8:34
pubmed: 24059252
JAMA. 2016 Sep 20;316(11):1211-1212
pubmed: 27654608
J Subst Abuse Treat. 2010 Sep;39(2):96-104
pubmed: 20598829
Health Serv Res. 2019 Apr;54(2):390-398
pubmed: 30665272
Curr Psychiatry Rep. 2011 Oct;13(5):374-81
pubmed: 21773951
J Rural Health. 2010 Summer;26(2):129-38
pubmed: 20446999
Cochrane Database Syst Rev. 2011 Oct 05;(10):CD004147
pubmed: 21975742
Addiction. 2004 Aug;99(8):999-1014
pubmed: 15265097
Health Aff (Millwood). 2015 Jun;34(6):1028-34
pubmed: 26056209
N Engl J Med. 2014 May 29;370(22):2063-6
pubmed: 24758595
MMWR Morb Mortal Wkly Rep. 2016 Dec 30;65(50-51):1445-1452
pubmed: 28033313
JAMA Psychiatry. 2014 Feb;71(2):190-6
pubmed: 24369387
J Addict Med. 2015 Sep-Oct;9(5):358-67
pubmed: 26406300
Cochrane Database Syst Rev. 2011 Sep 07;(9):CD005031
pubmed: 21901695
Addict Behav. 2011 Jun;36(6):584-589
pubmed: 21377275